Merck & Co. (MRK): ‘Forget It… It’s China,’ Jim Cramer on Vaccine Rollout Woes
We recently published a list of Jim Cramer Discussed These 12 Stocks Recently. In this article, we are going to take a look ...
Merck shares plunge as company pauses Gardasil vaccine shipments in China, hurting 2025 outlook
Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...
Merck Stock Loses 9% on Vaccine Shipment Halt to China
Merck & Co. (MRK) stock lost over 9% yesterday on announcing a temporary shipment halt of its Gardasil vaccine to China. The ...
STAT5d
Merck’s earnings miss focused attention on Gardasil. The real issue is Keytruda
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
Merck’s struggles with HPV vaccine send stock to worst selloff in almost 17 years
Merck’s stock tumbled 6% early Tuesday, after the drug company’s softer-than-expected guidance for the current year offset ...
Merck 2025 sales forecast underwhelms as it pauses Gardasil sales in China
Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...
Personalized vaccine offers hope for patients with late-stage kidney cancer, clinical trial shows
Cancer researchers are one step closer to developing an effective vaccine to treat people with clear cell renal cell ...
Fact-checking Warren's claim about RFK Jr.'s work on vaccine lawsuits
During health secretary nominee Robert F. Kennedy Jr.'s Jan. 29 Senate confirmation hearing, Sen. Elizabeth Warren, D-Mass., ...
Merck stops Gardasil shipments to China, hitting 2025 outlook; shares tumble
Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for the HPV vaccine there is expected to hurt 2025 revenue, but it still posted a strong ...
BioPharma Dive4d
Merck shares tumble as company pauses Gardasil shipments to China
Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.
Merck's Gardasil Vaccine Slowdown In China Bites Again, Stock Falls On Weak 2025 Outlook
Merck posted Q4 sales of $15.62 billion, driven by Keytruda's 19% growth. FY25 guidance lags estimates, citing Gardasil ...
Merck Shares Hit After Guidance Falls Short, Gardasil Challenge
The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...